Currently, new thrombolytic drugs for stroke include teneplase. According to guideline recommendations, atieprepsin is the first choice for thrombolysis in stroke, followed by nalteplase, and other types of thrombolytic drugs are not recommended. The safety and efficacy of intravenous teneplase for the treatment of mild stroke is similar to, but not superior to, alteplase. Teneplase can be considered for patients with mild neurologic deficits without intracranial macrovascular occlusion, and the use of other thrombolytic drugs outside of clinical trials is not recommended. Adverse effects of teneplase are bleeding, allergic rash, shock, arrhythmia, pulmonary edema, heart failure, pericarditis, etc. Teneplase is contraindicated in patients with active hemorrhage, intracranial aneurysm, those who have had intracranial or vertebral surgery within 2 months, and patients with severe uncontrolled hypertension. Teneplase is a new drug for thrombolysis in stroke, and it is recommended that patients should seek medical treatment in time if they are unwell, and use medication under the guidance of physicians.